ORGO - Organogenesis Holdings Inc.
NASDAQ
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
Canton,
United States
Type: Equity
ORGO price evolution
ORGO
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $94.34 | $90.48 | $89.35 | $104.34 |
| Short term investments | ||||
| Net receivables | $101.27 | $105.94 | $96.15 | $82 |
| Inventory | $27.04 | $26.88 | $27.69 | $28.25 |
| Total current assets | $238.51 | $234.19 | $227.17 | $225.04 |
| Long term investments | ||||
| Property, plant & equipment | $124.81 | $126.52 | $152.86 | $156.35 |
| Goodwill & intangible assets | $42.91 | $43.74 | $44.64 | |
| Total noncurrent assets | $208.97 | $231.31 | $234.98 | |
| Total investments | ||||
| Total assets | $446.3 | $443.16 | $458.48 | $460.02 |
| Current liabilities | ||||
| Accounts payable | $23.97 | $29.39 | $23.23 | $30.72 |
| Deferred revenue | ||||
| Short long term debt | $18.32 | $19.81 | $19.71 | |
| Total current liabilities | $77.28 | $85.73 | $82.8 | $80.51 |
| Long term debt | $57.17 | $92.67 | $96.41 | $99.64 |
| Total noncurrent liabilities | $93.94 | $97.65 | $100.85 | |
| Total debt | $110.99 | $116.22 | $119.35 | |
| Total liabilities | $167.75 | $179.66 | $180.45 | $181.36 |
| Shareholders' equity | ||||
| Retained earnings | -$47.78 | -$60.11 | -$43.07 | -$40.97 |
| Other shareholder equity | ||||
| Total shareholder equity | $263.5 | $278.03 | $278.66 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $104.34 | $102.48 | $114.53 | $84.81 |
| Short term investments | ||||
| Net receivables | $82 | $89.45 | $82.46 | $56.8 |
| Inventory | $28.25 | $24.78 | $25.02 | $27.8 |
| Total current assets | $225.04 | $222.61 | $226.98 | $174.34 |
| Long term investments | ||||
| Property, plant & equipment | $156.35 | $145.66 | $128.3 | $60.07 |
| Goodwill & intangible assets | $44.64 | $49.56 | $54.45 | $59.39 |
| Total noncurrent assets | $234.98 | $226.75 | $216.28 | $120.15 |
| Total investments | ||||
| Total assets | $460.02 | $449.36 | $443.26 | $294.49 |
| Current liabilities | ||||
| Accounts payable | $30.72 | $32.33 | $29.34 | $23.38 |
| Deferred revenue | ||||
| Short long term debt | $19.71 | $16.25 | $14.64 | $20.29 |
| Total current liabilities | $80.51 | $75.02 | $82 | $68.22 |
| Long term debt | $99.64 | $66.23 | $117.66 | $64.49 |
| Total noncurrent liabilities | $100.85 | $108.67 | $119.22 | $80.19 |
| Total debt | $119.35 | $123.79 | $132.3 | $84.77 |
| Total liabilities | $181.36 | $183.69 | $201.22 | $148.41 |
| Shareholders' equity | ||||
| Retained earnings | -$40.97 | -$45.3 | -$60.13 | -$153.06 |
| Other shareholder equity | ||||
| Total shareholder equity | $278.66 | $265.67 | $242.03 | $146.08 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $115.18 | $130.23 | $109.98 | $99.65 |
| Cost of revenue | $29.2 | $28.7 | $27.77 | |
| Gross Profit | $88.38 | $101.04 | $81.28 | $71.88 |
| Operating activities | ||||
| Research & development | $15.59 | $12.81 | $11.77 | |
| Selling, general & administrative | $76.54 | $72.32 | $61.38 | |
| Total operating expenses | $82.14 | $114.96 | $85.11 | $73.23 |
| Operating income | -$13.92 | -$3.83 | -$1.35 | |
| Income from continuing operations | ||||
| EBIT | -$13.92 | -$3.83 | -$1.29 | |
| Income tax expense | -$6.51 | $2.5 | -$2.24 | -$1.23 |
| Interest expense | -$0.47 | $0.62 | $0.51 | $0.5 |
| Net income | ||||
| Net income | $12.33 | -$17.04 | -$2.1 | -$0.57 |
| Income (for common shares) | -$17.04 | -$2.1 | -$0.57 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $433.14 | $450.89 | $468.06 | $338.3 |
| Cost of revenue | $106.48 | $105.02 | $114.2 | $87.32 |
| Gross Profit | $326.66 | $345.87 | $353.86 | $250.98 |
| Operating activities | ||||
| Research & development | $44.38 | $39.76 | $30.74 | $20.09 |
| Selling, general & administrative | $269.75 | $283.81 | $250.2 | $203.48 |
| Total operating expenses | $314.13 | $323.57 | $280.94 | $223.47 |
| Operating income | $12.53 | $22.3 | $72.92 | $27.51 |
| Income from continuing operations | ||||
| EBIT | $12.58 | $22.29 | $71.02 | $29.76 |
| Income tax expense | $5.45 | $4.75 | -$31.12 | $0.53 |
| Interest expense | $2.19 | $2.01 | $7.24 | $11.28 |
| Net income | ||||
| Net income | $4.95 | $15.53 | $94.9 | $17.95 |
| Income (for common shares) | $4.95 | $15.53 | $94.9 | $17.95 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$17.04 | -$2.1 | -$0.57 | |
| Operating activities | ||||
| Depreciation | $6.36 | $6.18 | $6.33 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $2.57 | $2.41 | $2.37 | |
| Total cash flows from operations | $4.74 | -$10.16 | $10.61 | |
| Investing activities | ||||
| Capital expenditures | -$1.88 | -$2.22 | -$3.32 | |
| Investments | ||||
| Total cash flows from investing | -$6.67 | -$1.88 | -$2.22 | -$3.32 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.18 | |||
| Net borrowings | -$1.67 | -$1.67 | -$1.78 | |
| Total cash flows from financing | -$6.01 | -$1.73 | -$2.61 | -$1.78 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$9.41 | $1.13 | -$14.99 | $5.51 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $4.95 | $15.53 | $94.9 | $17.95 |
| Operating activities | ||||
| Depreciation | $23.45 | $18.03 | $16.68 | $7.47 |
| Business acquisitions & disposals | -$3.69 | |||
| Stock-based compensation | $9 | $6.55 | $3.86 | $1.66 |
| Total cash flows from operations | $30.92 | $24.86 | $61.98 | $6.8 |
| Investing activities | ||||
| Capital expenditures | -$24.36 | -$33.9 | -$31.22 | -$21.14 |
| Investments | ||||
| Total cash flows from investing | -$24.36 | -$33.9 | -$31.22 | -$24.83 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $2.07 | $2.2 | $61.9 | |
| Net borrowings | -$5.17 | -$3.01 | -$2.01 | -$15.91 |
| Total cash flows from financing | -$5.5 | -$2.2 | -$1.04 | $42.47 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $1.05 | -$11.24 | $29.72 | $24.44 |
News
Fundamentals
| Market cap | $539.59M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 132.58M |
| Revenue | $455.04M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$7.38M |
| Revenue Q/Q | 6.12% |
| Revenue Y/Y | 1.34% |
| P/E ratio | -73.11 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 1.19 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | 0.71 |
| EPS | -$0.06 |
|---|---|
| ROA | -1.63% |
| ROE | N/A |
| Debt/Equity | 0.65 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 3.09 |
| Quick ratio | 2.74 |